GGrantIndex
← Leaderboards

Matthias G. Von Herrath

Scripps Research Institute

$21,559,291
Attributed
$23,316,791
Total exposure
21
Grants
16
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.5M · FY200522
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$33,754,473 · 23

By mechanism

R01$13,779,026 · 6
P01$10,234,179 · 6
U01$4,832,224 · 2
U19$4,406,285 · 3
R21$280,050 · 1
R29$180,329 · 1

Top collaborators

Most similar at Scripps Research Institute

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsBaseInsulinCytokineT-LymphocyteCollaborationsAntigensIsletImmuneInterferonsPancreasAutoimmunityDiabetes MellitusInsightBeta CellInsulin-Dependent Diabetes MellitusImmunotherapyResponseIn VivoProductionGenerationsVirus DiseasesAutoimmune DiseasesCd8b1 Gene

Grant awards (91)

Integrated Functional Histopathology of the Diabetic Human Pancreas$699,000
R01 · FY2022 · AI · contact PI
Integrated Functional Histopathology of the Diabetic Human Pancreas$699,000
R01 · FY2021 · AI · contact PI
Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 Diabetes$450,000
R01 · FY2021 · AI · contact PI
Integrated Functional Histopathology of the Diabetic Human Pancreas$699,000
R01 · FY2020 · AI · contact PI
Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 Diabetes$450,000
R01 · FY2020 · AI · contact PI
Integrated Functional Histopathology of the Diabetic Human Pancreas$699,000
R01 · FY2019 · AI · contact PI
Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 Diabetes$450,000
R01 · FY2019 · AI · contact PI
Integrated Functional Histopathology of the Diabetic Human Pancreas$719,000
R01 · FY2018 · AI · contact PI
Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 Diabetes$450,000
R01 · FY2018 · AI · contact PI
Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 Diabetes$450,000
R01 · FY2017 · AI · contact PI
Assessment of cytokines in human islets from patients with diabetes$429,400
U01 · FY2016 · AI · contact PI
Assessment of cytokines in human islets from patients with diabetes$429,400
U01 · FY2015 · AI · contact PI
Specificity of CD8 cells in islets from type 1 diabetes patients$401,400
R01 · FY2015 · AI · contact PI
Treg stability in viral infection and autoimmunity$465,255
P01 · FY2014 · AI · contact PI
Assessment of cytokines in human islets from patients with diabetes$429,400
U01 · FY2014 · AI · contact PI
Specificity of CD8 cells in islets from type 1 diabetes patients$401,400
R01 · FY2014 · AI · contact PI
Treg stability in viral infection and autoimmunity$437,339
P01 · FY2013 · AI · contact PI
Assessment of cytokines in human islets from patients with diabetes$423,056
U01 · FY2013 · AI · contact PI
Specificity of CD8 cells in islets from type 1 diabetes patients$377,316
R01 · FY2013 · AI · contact PI
Treg stability in viral infection and autoimmunity$465,255
P01 · FY2012 · AI · contact PI
Assessment of cytokines in human islets from patients with diabetes$447,650
U01 · FY2012 · AI · contact PI
Specificity of CD8 cells in islets from type 1 diabetes patients$401,400
R01 · FY2012 · AI · contact PI
Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes$486,604
U01 · FY2011 · DK · contact PI
Treg stability in viral infection and autoimmunity$405,149
P01 · FY2011 · AI · contact PI
Specificity of CD8 cells in islets from type 1 diabetes patients$401,400
R01 · FY2011 · AI · contact PI
Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes$457,376
U01 · FY2010 · DK · contact PI
How IL-10R blockade can resolve persistent viral infections$412,999
R01 · FY2010 · AI · contact PI
Treg stability in viral infection and autoimmunity$411,539
P01 · FY2010 · AI · contact PI
Viruses and Autoimmunity POI$457,032
P01 · FY2009 · AI · contact PI
Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes$444,056
U01 · FY2009 · DK · contact PI
How IL-10R blockade can resolve persistent viral infections$417,170
R01 · FY2009 · AI · contact PI
How IL-10R blockade can resolve persistent viral infections$207,044
R01 · FY2009 · AI · contact PI
CXCR3 Chemokines in Type I Diabetes$16,638
R01 · FY2009 · DK · contact PI
FASEB Summer Conference on 'Autoimmunity'$10,000
R13 · FY2009 · AI · contact PI
Viruses and Autoimmunity POI$1,130,078
P01 · FY2008 · AI · contact PI
Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes$431,123
U01 · FY2008 · DK · contact PI
How IL-10R blockade can resolve persistent viral infections$417,170
R01 · FY2008 · AI · contact PI
CXCR3 Chemokines in Type I Diabetes$290,121
R01 · FY2008 · DK · contact PI
How do Viral Infections induce and/or enhance autoimmunity$245,786
P01 · FY2008 · AI · contact PI
CORE--Tetramer Core$35,406
P01 · FY2008 · AI · contact PI
FASEB Summer Conference on 'Autoimmunity'$5,001
R13 · FY2008 · AI · contact PI
Viruses and Autoimmunity POI$1,112,562
P01 · FY2007 · AI · contact PI
Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes$427,109
U01 · FY2007 · DK · contact PI
How IL-10R blockade can resolve persistent viral infections$425,250
R01 · FY2007 · AI · contact PI
CXCR3 Chemokines in Type I Diabetes$296,042
R01 · FY2007 · DK · contact PI
Role of a Non-Tolerant Autoantigen in Autoimmunity$269,947
R01 · FY2007 · AI · contact PI
How do Viral Infections induce and/or enhance autoimmunity$241,978
P01 · FY2007 · AI · contact PI
CORE--Tetramer Core$34,860
P01 · FY2007 · AI · contact PI
VISUALIZATION OF PANCREATIC T CELL TRAFFICKING DURING DIABETES DEVELOPMENT$4,340
P41 · FY2007 · RR · contact PI
Viruses and Autoimmunity POI$1,116,043
P01 · FY2006 · AI · contact PI
Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes$427,050
U01 · FY2006 · DK · contact PI
CXCR3 Chemokines in Type I Diabetes$304,883
R01 · FY2006 · DK · contact PI
Role of a Non-Tolerant Autoantigen in Autoimmunity$278,010
R01 · FY2006 · AI · contact PI
DNA Vaccination & Regulatory Cells in Type I Diabetes$270,979
R01 · FY2006 · DK · contact PI
How do Viral Infections induce and/or enhance autoimmunity$246,953
P01 · FY2006 · AI · contact PI
CORE--Tetramer Core$35,584
P01 · FY2006 · AI · contact PI
Animal Models in Type 1 Diabetes and Multiple Sclerosis$21,000
R13 · FY2006 · DK · contact PI
VISUALIZATION OF PANCREATIC T CELL TRAFFICKING DURING DIABETES DEVELOPMENT$2,039
P41 · FY2006 · RR · contact PI
Viruses and Autoimmunity POI$1,102,268
P01 · FY2005 · AI
How Does blockade of CD40/CD40L Prevent Autoimmunity?$958,901
U19 · FY2005 · AI
CXCR3 Chemokines in Type I Diabetes$307,122
R01 · FY2005 · DK
IMMUNE TOLERANCE INDUCTION BY APOPTOTIC BODIES$280,050
R21 · FY2005 · AI
DNA Vaccination &Regulatory Cells in Type I Diabetes$277,500
R01 · FY2005 · DK
Role of a Non-Tolerant Autoantigen in Autoimmunity$277,500
R01 · FY2005 · AI
How do Viral Infections induce and/or enhance autoimmunity$239,738
P01 · FY2005 · AI
CORE--Tetramer Core$34,544
P01 · FY2005 · AI
Viruses and Autoimmunity POI$1,113,414
P01 · FY2004 · AI
How Does blockade of CD40/CD40L Prevent Autoimmunity?$930,029
U19 · FY2004 · AI
CXCR3 Chemokines in Type I Diabetes$307,122
R01 · FY2004 · DK
DNA Vaccination &Regulatory Cells in Type I Diabetes$277,500
R01 · FY2004 · DK
Role of a Non-Tolerant Autoantigen in Autoimmunity$277,500
R01 · FY2004 · AI
How do Viral Infections induce and/or enhance autoimmunity$242,163
P01 · FY2004 · AI
CORE--Tetramer Core$34,894
P01 · FY2004 · AI
How Does blockade of CD40/CD40L Prevent Autoimmunity?$871,082
U19 · FY2003 · AI
DNA Vaccination &Regulatory Cells in Type I Diabetes$277,500
R01 · FY2003 · DK
Role of a Non-Tolerant Autoantigen in Autoimmunity$138,750
R01 · FY2003 · AI
DNA Vaccination &Regulatory Cells in Type I Diabetes$8,325
R01 · FY2003 · DK
How Does blockade of CD40/CD40L Prevent Autoimmunity?$780,672
U19 · FY2002 · AI
EFFECTS OF AGING ON THE DEVELOPMENT AND TREATMENT OF AUTOIMMUNE DIABETES$178,517
P01 · FY2002 · AG
USE OF REGULATORY APCS TO INDUCE/MAINTAIN TOLERANCE$0
U19 · FY2002 · AI
CTB AND AUTOANTIGENS--T1D PREVENTION AFTER ORAL FEEDING$0
U19 · FY2002 · AI
How Does blockade of CD40/CD40L Prevent Autoimmunity?$865,601
U19 · FY2001 · AI
EFFECTS OF AGING ON THE DEVELOPMENT AND TREATMENT OF AUTOIMMUNE DIABETES$149,274
P01 · FY2001 · AG
PATHOGENESIS AND TREATMENT OF AUTOIMMUNE DIABETES$53,190
R29 · FY2001 · DK
CTB AND AUTOANTIGENS--T1D PREVENTION AFTER ORAL FEEDING$0
U19 · FY2001 · AI
USE OF REGULATORY APCS TO INDUCE/MAINTAIN TOLERANCE$0
U19 · FY2001 · AI
EFFECTS OF AGING ON THE DEVELOPMENT AND TREATMENT OF AUTOIMMUNE DIABETES$0
P01 · FY2001 · AG
REGULATION AND IMMUNOTHERAPY OF IDDM$276,038
R01 · FY2000 · AI
EFFECTS OF AGING ON THE DEVELOPMENT AND TREATMENT OF AUTOIMMUNE DIABETES$149,274
P01 · FY2000 · AG
EFFECTS OF AGING ON THE DEVELOPMENT AND TREATMENT OF AUTOIMMUNE DIABETES$149,274
P01 · FY2000 · AG
PATHOGENESIS AND TREATMENT OF AUTOIMMUNE DIABETES$127,139
R29 · FY2000 · DK